keyword
https://read.qxmd.com/read/38647198/rescuing-a-troubled-tolcapone-with-pegylated-plga-nanoparticles-design-characterization-and-hepatotoxicity-evaluation
#1
JOURNAL ARTICLE
Miguel Pinto, Cláudia Sofia Machado, Sandra Barreiro, Francisco J Otero-Espinar, Fernando Remião, Fernanda Borges, Carlos Fernandes
Tolcapone is an orally active catechol-O-methyltransferase (COMT) inhibitor used as adjuvant therapy in Parkinson's disease. However, it has a highly hepatotoxic profile, as recognized by the U.S. Food and Drug Administration. As a possible solution, nanoscience brought us several tools in the development of new functional nanomaterials with tunable physicochemical properties, which can be part of a solution to solve several drawbacks, including drug's short half-life and toxicity. This work aims to use PEGylated poly(lactic- co -glycolic acid) (PLGA) nanoparticles as a stable carrier with lower hydrodynamic size and polydispersity to encapsulate tolcapone in order to overcome its therapeutic drawbacks...
April 22, 2024: ACS Applied Materials & Interfaces
https://read.qxmd.com/read/38646931/advances-in-nanotechnology-for-improving-the-targeted-delivery-and-activity-of-amphotericin-b-2011-2023-a-systematic-review
#2
REVIEW
Tahereh Zadeh Mehrizi, Nariman Mossafa, Mohammad Vodjgani, Hasan Ebrahimi Shahmabadi
Amphotericin B (AmB) is a broad-spectrum therapeutic and effective drug, but it has serious side effects of toxicity and solubility. Therefore, reducing its toxicity should be considered in therapeutic applications. Nanotechnology has paved the way to improve drug delivery systems and reduce toxicity. The present study, for the first time, comprehensively reviews the studies from 2011 to 2023 on reducing the in vitro toxicity of AmB. The findings showed that loading AmB with micellar structures, nanostructured lipid carriers, liposomes, emulsions, poly lactide-co-glycolide acid, chitosan, dendrimers, and other polymeric nanoparticles increases the biocompatibility and efficacy of the drug and significantly reduces toxicity...
April 22, 2024: Nanotoxicology
https://read.qxmd.com/read/38645492/liposomal-factor-viii-as-an-efficient-pharmaceutical-system-for-the-treatment-of-hemophilia
#3
JOURNAL ARTICLE
Maryam Karimi, Seyed Mahdi Rezayat, Seyed Alireza Mortazavi, Azadeh Haeri, Mahmoud Reza Jaafari
OBJECTIVES: Currently, the most important treatment approach for hemophilia type A is recombinant Factor VIII. However, due to its low retention time in the blood, the patients usually need successive injections. In addition, neutralization of injected proteins by antibodies complicates treatment. We examined the prolongation of the persistence time of injectable FVIII in the blood and the potential effects on survival using promising PEGylated liposomes (PEGLip) utilizing hydrogenated soy phosphatidylcholine (HSPC, Tm= 54...
2024: Iranian Journal of Basic Medical Sciences
https://read.qxmd.com/read/38643811/prolonged-delivery-of-hiv-1-vaccine-nanoparticles-from-hydrogels
#4
JOURNAL ARTICLE
Raphael Mietzner, Clara Barbey, Heike Lehr, Christian E Ziegler, David Peterhoff, Ralf Wagner, Achim Goepferich, Miriam Breunig
Immunization is a straightforward concept but remains for some pathogens like HIV-1 a challenge. Thus, new approaches towards increasing the efficacy of vaccines are required to turn the tide. There is increasing evidence that antigen exposure over several days to weeks induces a much stronger and more sustained immune response compared to traditional bolus injection, which usually leads to antigen elimination from the body within a couple of days. Therefore, we developed a poly(ethylene) glycol (PEG) hydrogel platform to investigate the principal feasibility of a sustained release of antigens to mimic natural infection kinetics...
April 19, 2024: International Journal of Pharmaceutics
https://read.qxmd.com/read/38642859/positron-emission-tomography-guided-synergistic-treatment-of-melanoma-using-multifunctional-zirconium-hematoporphyrin-nanosonosensitizers
#5
JOURNAL ARTICLE
Xiaodan Jiao, Xiaoyang Li, Yan Du, Yiyang Cong, Shuyang Yang, Daiqin Chen, Tao Zhang, Min Feng, Hao Hong
Sonodynamic therapy (SDT) has emerged as a useful approach for tumor treatment. However, its widespread application is impeded by poor pharmacokinetics of existing sonosensitizers. Here we developed a metal-organic nanoplatform, wherein a small-molecule sonosensitizer (hematoporphyrin monomethyl ether, HMME) was ingeniously coordinated with zirconium, resulting in a multifunctional nanosonosensitizer termed Zr-HMME. Through post-synthetic modifications involving PEGylation and tumor-targeting peptide (F3) linkage, a nanoplatform capable of homing on melanoma was produced, which could elicit robust immune responses to suppress tumor lung metastasis in the host organism...
April 18, 2024: Journal of Controlled Release
https://read.qxmd.com/read/38641023/quantitative-hbeag-is-a-strong-predictor-of-hbeag-loss-among-patients-receiving-pegylated-interferon
#6
JOURNAL ARTICLE
Daniel Q Huang, Liang Shen, Wah Wah Phyo, Gavin Cloherty, Emily K Butler, Mary C Kuhns, Anne L McNamara, Vera Holzmayer, Jeffrey Gersch, Mark Anderson, Wei Lyn Yang, Jing Hieng Ngu, Jason Chang, Jessica Tan, Taufique Ahmed, Yock Young Dan, Yin Mei Lee, Guan Huei Lee, Poh Seng Tan, Mark Muthiah, Htet Toe Wai Khine, Chris Lee, Amy Tay, Seng Gee Lim
BACKGROUND: HBeAg loss is an important endpoint for antiviral therapy in chronic hepatitis B (CHB), however there are no reliable biomarkers to identify patients who will respond to the addition of pegylated interferon to nucleos(t)ide analogue (NA) therapy. AIM: To evaluate the use of serum biomarkers to predict HBeAg loss. METHODS: HBeAg positive CHB participants on NAs who switched-to or added-on 48 weeks pegylated interferon alpha2b (clinicaltrial...
April 17, 2024: Antiviral Research
https://read.qxmd.com/read/38639647/alleviation-of-doxorubicin-adverse-effects-via-loading-into-various-drug-delivery-systems-a-comparative-study
#7
JOURNAL ARTICLE
Rehab M Abdel-Megeed, Hassan Z Ghanem, Mai O Kadry
Aim: Drug resistance is still a significant barrier to effective hepatocellular carcinoma therapy. Address the issue of doxorubicin resistance and inter-receptor crosstalk various doxorubicin formulations were investigated. Methods: Hepatocellular carcinoma was carried out using 3-methylechloroanthrene. Animals were then treated with doxorubicin, liposomal doxorubicin, titanium-loaded doxorubicin (TiO2-Dox), lactoferrin-doxorubicin and PEGylated doxorubicin. Biochemical and molecular analyses were assessed...
April 19, 2024: Therapeutic Delivery
https://read.qxmd.com/read/38638908/prophylactic-treatment-with-pegylated-bovine-ifn%C3%AE-3-effectively-bridges-the-gap-in-vaccine-induced-immunity-against-fmd-in-cattle
#8
JOURNAL ARTICLE
Sarah E Attreed, Christina Silva, Monica Rodriguez-Calzada, Aishwarya Mogulothu, Sophia Abbott, Paul Azzinaro, Peter Canning, Lillian Skidmore, Jay Nelson, Nick Knudsen, Gisselle N Medina, Teresa de Los Santos, Fayna Díaz-San Segundo
Foot-and-mouth disease (FMD) is a vesicular disease of cloven-hoofed animals with devastating economic implications. The current FMD vaccine, routinely used in enzootic countries, requires at least 7 days to induce protection. However, FMD vaccination is typically not recommended for use in non-enzootic areas, underscoring the need to develop new fast-acting therapies for FMD control during outbreaks. Interferons (IFNs) are among the immune system's first line of defense against viral infections. Bovine type III IFN delivered by a replication defective adenovirus (Ad) vector has effectively blocked FMD in cattle...
2024: Frontiers in Microbiology
https://read.qxmd.com/read/38634114/toward-distinguishing-between-the-superchaotropic-and-hydrophobic-characters-of-nanometric-sized-ions-in-interaction-with-pegylated-surfaces
#9
JOURNAL ARTICLE
Christoph Bruckschlegel, Coralie Pasquier, Guillaume Toquer, Luc Girard, Michael Odorico, Joseph Lautru, Olivier Diat, Pierre Bauduin
In this study, we explore the superchaotropic effect of various polyoxometalate or boron cluster nano-ions on hydrophilic neutral surfaces. Nano-ions, characterized by low charge densities, exhibit strong adsorption on non-ionic hydrophilic surfaces like PEGylated micelles. This adsorption phenomenon was attributed to the enthalpically favorable dehydration of nano-ions, the so-called superchaotropic effect. Here, we investigate the adsorption of three nano-ions, α-SiW12 O40 4- , α-PW12 O40 3- , and B12 I12 2- , with decreasing charge density or increasing superchaotropicity (or hydrophobicity), on hydrophilic solid surfaces, PEGylated gold nanoparticles, and PEGylated gold-coated quartz crystal...
April 18, 2024: Journal of Physical Chemistry Letters
https://read.qxmd.com/read/38633851/new-treatment-options-in-chronic-hepatitis-b-how-close-are-we-to-cure
#10
REVIEW
Pınar Korkmaz, Ali Asan, Faruk Karakeçili, Süda Tekin, Neşe Demirtürk
Hepatitis B virus (HBV) infection is the leading cause of chronic liver disease worldwide. HBV-infected patients are at a lifetime risk of developing liver cirrhosis and hepatocellular carcinoma (HCC). Today, pegylated interferon (Peg-IFN) and nucleos(t)ide analogs (NAs) are used in the treatment of patients with chronic hepatitis B (CHB). Both treatment options have limitations. Despite effective viral suppression, NAs have little effect on covalently closed circular DNA (cccDNA), the stable episomal form of the HBV genome in hepatocytes...
December 2023: Infect Dis Clin Microbiol
https://read.qxmd.com/read/38630629/herb-extracellular-vesicle-chitosan-pegylated-graphene-oxide-conjugate-delivers-estrogen-receptor-%C3%AE-targeting-sirna-to-breast-cancer-cells
#11
JOURNAL ARTICLE
Saroj Saroj, Poornima Us, Sachin Patil, Debashish Paul, Sunita Saha, Akbar Ali, Suchetan Pal, Bimlesh Lochab, Tatini Rakshit
Herb-based extracellular vesicles (EV), inherently replete with bioactive proteins, RNA, lipids, and other medicinal compounds, are noncytotoxic and uniquely capable of cellular delivery to meet the ever-stringent challenges of ongoing clinical applications. EVs are abundant in nature, affordable, and scalable, but they are also incredibly fragile and stuffed with many biomolecules. To address the low drug binding abilities and poor stability of EVs, we demonstrated herb-based EVs (isolated from neem, mint, and curry leaves) conjugated with chitosan (CS) and PEGylated graphene oxide (GP) that led to their transformation into robust and efficient vectors...
April 17, 2024: ACS Applied Bio Materials
https://read.qxmd.com/read/38629735/overcoming-the-blood-brain-tumor-barrier-with-docetaxel-loaded-mesoporous-silica-nanoparticles-for-treatment-of-temozolomide-resistant-glioblastoma
#12
JOURNAL ARTICLE
Tsung-I Hsu, Yi-Ping Chen, Rong-Lin Zhang, Zih-An Chen, Cheng-Hsun Wu, Wen-Chang Chang, Chung-Yuan Mou, Hardy Wai-Hong Chan, Si-Han Wu
While temozolomide (TMZ) has been a cornerstone in the treatment of newly diagnosed glioblastoma (GBM), a significant challenge has been the emergence of resistance to TMZ, which compromises its clinical benefits. Additionally, the nonspecificity of TMZ can lead to detrimental side effects. Although TMZ is capable of penetrating the blood-brain barrier (BBB), our research addresses the need for targeted therapy to circumvent resistance mechanisms and reduce off-target effects. This study introduces the use of PEGylated mesoporous silica nanoparticles (MSN) with octyl group modifications (C8-MSN) as a nanocarrier system for the delivery of docetaxel (DTX), providing a novel approach for treating TMZ-resistant GBM...
April 17, 2024: ACS Applied Materials & Interfaces
https://read.qxmd.com/read/38626918/unique-advantages-of-dendrimers-structured-mesoporous-silica-nanoparticles-over-traditional-hollow-ones-in-delivering-bcl2-functional-converting-peptide-for-multidrug-resistant-cancer-treatment
#13
JOURNAL ARTICLE
Yuehuang Wu, Fangmei Ma, Lixue Yu, Ruimiao Lin, Sijin Lin, Zhihan Guo, Min Zhou, Mingyu Li, Yi Zhang, Jingjing Xie
Innovative silica nanomaterials have made the significant advancements in curative therapy against cancers with multidrug resistance (MDR). The study on different-nanostructured mesoporous silica nanoparticles (MSNs) with discrepant pore sizes affecting biomacromolecules in resisting cancer MDR hasn't been reported yet. In this study, a systematic comparison of 6 nm-pore sized hollow-structured MSNs (HMSNs) and 10 nm-pore sized dendrimers-structured MSNs (LMSNs) for delivering Bcl-2-functional converting peptide (N9) or doxorubicin (DOX) to overcome cancer MDR was comprehensively carried out both in in vitro and in vivo resistant tumor models...
April 16, 2024: Advanced Healthcare Materials
https://read.qxmd.com/read/38622733/correction-targeting-of-focal-adhesion-kinase-enhances-the-immunogenic-cell-death-of-pegylated-liposome-doxorubicin-to-optimize-therapeutic-responses-of-immune-checkpoint-blockade
#14
Baoyuan Zhang, Ning Li, Jiaming Gao, Yuxi Zhao, Jun Jiang, Shuang Xie, Cuiping Zhang, Qingyu Zhang, Leo Liu, Zaiqi Wang, Dongmei Ji, Lingying Wu, Ruibao Ren
No abstract text is available yet for this article.
April 16, 2024: Journal of Experimental & Clinical Cancer Research: CR
https://read.qxmd.com/read/38621615/deciphering-the-monocyte-targeting-mechanisms-of-pegylated-cationic-liposomes-by-investigating-the-biomolecular-corona
#15
JOURNAL ARTICLE
Rasmus Münter, Martin Bak, Mikkel E Thomsen, Ladan Parhamifar, Allan Stensballe, Jens B Simonsen, Kasper Kristensen, Thomas L Andresen
Cationic liposomes specifically target monocytes in blood, rendering them promising drug-delivery tools for cancer immunotherapy, vaccines, and therapies for monocytic leukaemia. The mechanism behind this monocyte targeting ability is, however, not understood, but may involve plasma proteins adsorbed on the liposomal surfaces. To shed light on this, we investigated the biomolecular corona of three different types of PEGylated cationic liposomes, finding all of them to adsorb hyaluronan-associated proteins and proteoglycans upon incubation in human blood plasma...
April 13, 2024: International Journal of Pharmaceutics
https://read.qxmd.com/read/38621603/the-impact-of-phospholipids-with-high-transition-temperature-to-enhance-redox-sensitive-liposomal-doxorubicin-efficacy-in-colon-carcinoma-model
#16
JOURNAL ARTICLE
Elaheh Mirhadi, Anis Askarizadeh, Leila Farhoudi, Mohammad Mashreghi, Saeed Behboodifar, Seyedeh Hoda Alavizadeh, Leila Arabi, Mahmoud Reza Jaafari
In this study, we have developed a redox-sensitive (RS) liposomal doxorubicin formulation by incorporating 10,10'-diselanediylbis decanoic acid (DDA) organoselenium compound as the RS moiety. Hence, several RS liposomal formulations were prepared by using DOPE, HSPC, DDA, mPEG2000 -DSPE, and cholesterol. In situ drug loading using a pH gradient and citrate complex yielded high drug to lipid ratio and encapsulation efficiency (100%) for RS liposomes. Liposomal formulations were characterized in terms of size, surface charge and morphology, drug loading, release properties, cell uptake and cytotoxicity, as well as therapeutic efficacy in BALB/c mice bearing C26 tumor cells...
April 13, 2024: Chemistry and Physics of Lipids
https://read.qxmd.com/read/38617334/cas9-rnp-physiochemical-analysis-for-enhanced-crispr-aunp-assembly-and-function
#17
Daniel D Lane, Karthikeya S V Gottimukkala, Rachel A Cunningham, Shirley Jwa, Molly E Cassidy, Jack M P Castelli, Jennifer E Adair
CRISPR therapy for hematological disease has proven effective for transplant dependent beta thalassemia and sickle cell anemia, with additional disease targets in sight. The success of these therapies relies on high rates of CRISPR-induced double strand DNA breaks in hematopoietic stem and progenitor cells (HSPC). To achieve these levels, CRISPR complexes are typically delivered by electroporation ex vivo which is toxic to HSPCs. HSPCs are then cultured in stimulating conditions that promote error-prone DNA repair, requiring conditioning with chemotherapy to facilitate engraftment after reinfusion...
April 2, 2024: bioRxiv
https://read.qxmd.com/read/38617106/the-forgotten-virus-hepatitis-d-a-review-of-epidemiology-diagnosis-and-current-treatment-strategies
#18
REVIEW
Adam Khattak, Tahne Vongsavath, Lubaba Haque, Amrit Narwan, Robert G Gish
Hepatitis D virus (HDV) is an RNA subvirus that infects patients with co-existing hepatitis B virus (HBV) infections. HDV burden is estimated to be approximately 15-20 million people worldwide. Despite HDV severity, screening for HDV remains inadequate. HDV screening would benefit from a revamped approach that automatically reflexes testing when individuals are diagnosed with HBV if HBsAg-positive, to total anti-HDV, and then to quantitative HDV-RNA polymerase chain reaction (PCR) rather than only testing those at high risk sequentially...
2024: Journal of Clinical and Experimental Hepatology
https://read.qxmd.com/read/38615483/phase-ii-randomized-trial-comparing-metronomic-anthracycline-containing-chemotherapy-versus-standard-schedule-in-untreated-her2-negative-advanced-breast-cancer-activity-and-quality-of-life-results-of-the-goim-21003-trial
#19
JOURNAL ARTICLE
Laura Orlando, Evaristo Maiello, Michele Orditura, Anna Diana, Giuliano Antoniol, Maria Grazia Morritti, Michele Aieta, Mariangela Ciccarese, Salvatore Pisconti, Roberto Bordonaro, Antonio Russo, Antonio Febbraro, Paola Schiavone, Annamaria Quaranta, Chiara Caliolo, Dario Loparco, Margherita Cinefra, Giuseppe Colucci, Saverio Cinieri
BACKGROUND: Optimizing chemotherapy to achieve disease and symptoms control is a noteworthy purpose in advanced breast cancer (ABC). We reported the activity and quality of life of a phase II study, comparing metronomic regimen with standard schedule as first line chemotherapy for ABC. METHODS: Patients with HER2 negative ABC were randomized to non-pegylated liposomal doxorubicin (NPLD, 60 mg/m2 every 3 weeks) and cyclophosphamide (CTX, 600 mg/m2 every 3 weeks) (Arm A) or NPLD (20 mg/m2 day, on day 1, 8 and 15 every 4 weeks) and metronomic daily oral CTX 50 mg (ARM B)...
April 5, 2024: Breast: Official Journal of the European Society of Mastology
https://read.qxmd.com/read/38614656/recent-treatment-advances-and-practical-management-of-hepatitis-d-virus
#20
REVIEW
Kathryn Olsen, Sara Mahgoub, Sarah Al-Shakhshir, Akram Algieder, Sowsan Atabani, Ayman Bannaga, Ahmed M Elsharkawy
Hepatitis D virus (HDV), also referred to as hepatitis delta virus, is the smallest virus capable of causing human disease. It is unable to replicate on its own and can only propagate in the presence of hepatitis B virus (HBV). Infection with both HBV and HDV frequently results in more severe disease than HBV alone, with higher instances of cirrhosis, liver failure and hepatocellular carcinoma (HCC). Thus, there is a need for effective treatment for HDV; however, currently approved treatment options are very limited both in terms of their efficacy and availability...
July 2023: Clinical Medicine: Journal of the Royal College of Physicians of London
keyword
keyword
41100
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.